Epidemiology and Semiology of Tumor-based Epilepsy December 2, 2012

Similar documents
Anticonvulsive therapy. Roberta Rudà Division of Neuro-Oncology, Dept. of Neuroscience City of Health and Science and University of Turin, Italy

Radioterapia no Tratamento dos Gliomas de Baixo Grau

Examining large groups of cancer patients to identify ways of predicting which therapies cancers might respond to.

Epilepsy and Brain Tumor. Apasri Lusawat M.D. Pediatric Neurology Prasat Neurological Institute

Chapter 1 Introduction

Chemotherapy in malignant brain tumors

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare

CNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS

Corporate Medical Policy

Intracranial Tumour Presenting with Varying Seizure Types

Seizure characteristics and prognostic factors of gliomas

Oncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013

Epidemiology and outcome research of glioma patients in Southern Switzerland: A population based analysis

MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES

Contemporary Management of Glioblastoma

MANAGEMENT N OF PRIMARY BRAIN TUMOURS IN THE ELDERLY

성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)

Glioma-associated epilepsy: toward mechanism-based treatment

SUPPLEMENTARY INFORMATION

Imaging for suspected glioma

Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

How genetic & biochemical alterations in brain tumors contribute to epileptogenesis

Does AED Prophylaxis Work in Posttraumatic Epilepsy December 2, 2012

EORTC (RTOG 0834 Endorsed) Opened: July 22, 2009

Ernie Somerville Prince of Wales Hospital EPILEPSY

PRESURGICAL EVALUATION. ISLAND OF COS Hippocrates: On the Sacred Disease. Disclosure Research-Educational Grants. Patients with seizure disorders

Brain Schema March 2018

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014

Precision medicine for gliomas

A clinical perspective on neuropathology and molecular genetics in brain tumors

Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide

NICE guideline Published: 11 July 2018 nice.org.uk/guidance/ng99

Perampanel in Drug-Resistant Epilepsy with Gliomas Seizure Response to Perampanel in Drug-resistant Epilepsy with Gliomas: Early Observations

Management of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS

Neuro-Oncology Program

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

University of Colorado Cancer Center Brain Disease Site Schema

Scottish Medicines Consortium

Pharmacological Treatment of Non-Lesional Epilepsy December 8, 2013

Expert Rev. Neurother. 8(6), xxx xxx (2008) Author Proof

Staging of Seizures According to Current Classification Systems December 10, 2013

2015 EUROPEAN CANCER CONGRESS

Dr H. Gharebaghian MD Neurologist Department of Neurology Kermanshah Faculty of Medicine

Brain tumours (primary) and brain metastases in adults

Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study

MOLECULAR DIAGNOSTICS OF GLIOMAS

CNS SESSION 3/8/ th Multidisciplinary Management of Cancers: A Case based Approach

Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment

Cilengitide (Impetreve) for glioblastoma multiforme. February 2012

2017 Diagnostic Slide Session Case 3

Brain and Spine Tumors

Tumors in Epilepsy. Abstract. Tumor Classification. Pathophysiology

Antibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008

Intracranial Studies Of Human Epilepsy In A Surgical Setting

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

University of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010

Brain Tumors. Andrew J. Fabiano, MD FAANS. Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine

CHINESE MEDICAL ASSOCIATION

Advancements in Neuro- Oncology

It s s Always Something!

Difficult to treat childhood epilepsy: Lessons from clinical case scenario

Chika Nwachukwu, Ph.D. MS IV Radiation Oncology Rotation

Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)

Efficacy of postoperative seizure prophylaxis in intra-axial brain tumor resections

Impact of Surgery on the Quality of Life in Patients with Primary Brain Tumors (A Review of 170 Patients at a Tertiary Care Hospital)

MRS and Perfusion of Brain Tumors

LOW GRADE ASTROCYTOMAS

Occurrence and Risk Factors for Post-traumatic Epilepsy in Civilian Poulations December 2, 2012

SEIZURE OUTCOME AFTER EPILEPSY SURGERY

Glioblastoma. In this fact sheet: What is a glioblastoma?

Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study

Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma

Update in Pediatric Epilepsy

Epilepsy in primary intracranial tumors in a neurosurgical hospital in Enugu, South East Nigeria

Drug Choice in New-Onset Epilepsy December 6, 2013

Prior to 1993, the only data available in the medical

Introduction to Neurosurgical Subspecialties:

Symptoms and problems in the End of Life Phase of High Grade Glioma Patients

Epilepsy is a frequent symptom in patients with

Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study

What yield in the last decade about Molecular Diagnostics in Neuro

CNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician

Epilepsy and EEG in Clinical Practice

CILENT P Leblond, DIPG Meeting, Barcelone 2012

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study

Accuracy of intra-operative rapid diagnosis by Squash smear in CNS lesions An early institutional experience. KK Bansal,

What are brain and spinal cord tumours? Contents

Low grade glioma: a journey towards a cure

Neuro-oncology Update Andrew Kokkino, MD Medical Director, The Neurosciences Institute at Sacred Heart at Riverbend May 20, 2013

CNS pathology Third year medical students. Dr Heyam Awad 2018 Lecture 12: CNS tumours 2/3

Febrile seizures. Olivier Dulac. Hôpital Necker-Enfants Malades, Université Paris V, INSERM U663

Understanding general brain tumor pathology, Part I: The basics. Craig Horbinski, M.D., Ph.D. Department of Pathology University of Kentucky

Glioblastoma: Current Treatment Approach 8/20/2018

General Identification. Name: 江 X X Age: 29 y/o Gender: Male Height:172cm, Weight: 65kg Date of admission:95/09/27

Supplementary Information

Who Gets Epilepsy? Etiologies and Risk Factors for Seizures. David Spencer, MD Professor of Neurology Director, OHSU Epilepsy Center Portland, OR

Imaging of Pediatric Epilepsy MRI. Epilepsy: Nonacute Situation

Transcription:

Epidemiology and Semiology of Tumor-based Epilepsy December 2, 2012 Charles J. Vecht, MD, PhD Medical Center The Hague SEIN Epilepsy Foundation, The Netherlands CHU Pitié-Salpêtrière, Paris, France American Epilepsy Society Annual Meeting

Disclosure Dr. Vecht has received Consultancy fees from UCB Pharma; Research Grants from UCB Pharma, Eisai and GlaxoSmithKline; Travel Funding from UCB Pharma. American Epilepsy Society Annual Meeting 2012

Published Papers on Epilepsy & Brain Tumors 1992-2001 2002-2011 Epilepsy 35.071 + 20,1 % Cancer 691.982 + 20,7 % Brain Tumors 35.377 Epilepsy & Br.Tumors + 20,9 % + 17,2 % 1.262 50.421 + 38,4 % 1.081.142 + 36,6 % 48.478 + 39,0 % 1.780 + 38,0 %

Epilepsy in Brain Tumours Epidemiology & Semiology Type of Seizures Type of Tumor Localization of Tumor Hereditary Tumors Systemic Cancer Prognostic Factors Underlying Mechanisms

Epilepsy in Brain Tumours Treatment Medical Management Prophylaxis of Seizures & Peri-operative Period Seizure Control with AEDs Treatment-Resistance Drug-Drug Interactions Anti-Tumor Therapy Surgery Radiation Therapy & Systemic Chemotherapy Interaction of AEDs with Tumor Control Toxicity Issues Side-Effects Quality of Life / Cognitive Changes

In General Population with New Onset Epilepsy Overall Frequency of Brain Tumors is 4 % Over 25 years of age 15 % Surgery for Intractable Epilepsy 12-25 % In Brain Tumors: Frequency of Epilepsy is > 40 % In Low-grade Brain Tumors Frequency of Epilepsy > 75 % Van Breemen 2007

In > 4 % Epilepsy in Systemic Cancer Metabolic Encephalopathies - Organ Dysfunction Toxic Encephalopathies - Iatrogenic Antibiotics, Interferons Systemic Chemotherapy (and Intrathecal & I.A.) Antidepressant & Neuroleptic Agents Often of Cumulative Nature (Co-Morbidities) Opportunistic CNS Infections Radionecrosis

100 Seizure Frequency in Brain Tumours 80 60 40 20 0 DNET GG LGA MG GBM MT PL LM DNET GG LGA MG GBM MT PL LM DYSEMBRYOBLASTIC NEURO-EPITHELIAL TUMOUR (DNET) GANGLIOGLIOMA LOW-GRADE ASTROCYTOMA (LOW-GRADE GLIOMA; LGG) MENINGIOMA GLIOBLASTOMA MULTIFORME (GBM) BRAIN METASTASIS PRIMARY CNS LYMPHOMA Van Breemen 2007 LEPTOMENINGEAL METASTASIS

Underlying Mechanisms Imbalance Adjacent Cortical Inhib. / Excit. Mechanisms Tumour Type: Developmental Tumors assoc. with Cortical Dysplasia and Well-diff. Cells, Time-course Aberrant Neuronal Migration, Synaptic Vesicles Glutamate, Glutamate-Decarboxylase, Gaba-Receptor Changes in Micro-environment: Angiogenesis, Perfusion, Hypoxia, ph Hypoxia: Lower Stability of DNA-Repair, Mutations Secondary Epileptogenesis: Temporal Location & Time Course

Disturbed Small Networks Patterns of connectivity loss in the gamma band in three patients (14, 10, and 2). Synchronization likelihood (SL) graphs were built at a threshold of 0.05 in the gamma band (30 60Hz). In the last column, the regions (dashed areas) showing a increase in missing connective points in comparison with control subjects (Z-score 1.96) are indicated. Bartolomei & Stam, 2006

Proportion of Drug-Resistant Epilepsies Gilioli 2012

Miller 2009

Calatozollo 2012

Association between MDR Protein Expression and Treatment-Response Calatozollo 2012

Seizure History in Low-Grade Glioma Sz. as Presenting Symptom is Favorable Prognostic Factor for Survival Van Veelen 1998; Smits 2011

Drug Interactions between Anti-Epileptic Drugs (AEDs) and Chemotherapeutic Drugs (CTDs)

First-Generation Antiepileptic Drugs Carbamazepine >95% hepatic Inducer Phenobarbital 75% hepatic, 25% renal Inducer Phenytoin >90% hepatic Inducer Valproate >95% hepatic Inhibitor Patsalos & Perucca 2003

Major CYP-450 Enzymes CYP 1A2 CYP 2E1 CYP 3A4 50% CYP 2D6 25% CYP 2C9 15% CYP 2C19 5% CYP 2C CYP 2D6 CYP 3A

Effect of Enzyme-Inducing AEDs on Pharmacokinetics of Chemotherapeutic Drugs Brodie et al, 2012

Survival of Children with B-lineage Leukaemia Relling 2000

Van den Bent 2009

P450 Drug-Drug Interactions Websites: http://medicine.iupui.edu/clinpharm/ddis/ http://en.wikipedia.org/wki/cytochrome_p450

Prophylactic AEDs Trials in Brain Tumors Forsyth Metast PHT AED 11/46 Placebo 15/54 OR (CI) 0.33-2.01 Glantz Metast Glioma VPA 13/37 9/37 0.61-4.63 Francesch etti Metast Glioma PHT PHB 3/41 4/22 0.07-1.76 North Metast Glioma PHT 9/42 5/39 0.56-6.12

Prophylaxis with LEV vs. PHT in 1 st Post- Operative Week LEV vs. PHT Seizures in 1st week Adverse Drug Reactions Sz. after 1 yr Follow-up Retent. Rate after 1 yr 1/ 105 vs. 9/ 210 (NS) 1/ 105 vs. 38/ 210 (p.001) 26 % vs. 36 % (NS) 64 % vs. 26 % (p.<03) Milligan 2008; Lim 2009

Spectrum of Low-Grade Epilepsy-Associated Tumors 144 (70 %) Classic Epilepsy-Associated Tumours 82 Ganglioglioma 29 Dysembryoblastic Neuroepithelial Tumour 33 Pilocytic Astrocytoma 5 Pleomorphic Xantho-astrocytoma 59 (27 %) Other Tumours 38 Astrocytomas gr II 17 Oligodendrogliomas gr II 4 (2 %) Grade III tumours 3 Astrocytoma gr III 1 Ganglioglioma gr III Luyken 2003

Seizure Characteristics in Low-Grade Glioma (n = 508) Mean Age 38.1 yrs 45 % Astrocytomas, 9 % Oligodendrogliomas, 46 % Oligo-Astrocytomas (LGG) Cortical Location 31 %, Subcortical 69 % Frontal 71 %, Temporal 37 %, Insular 21 %, Parietal 9% Pre-op Seizures 68.9 % Med. Duration of Sz. Onset and Surgery 10 Mos You 2012

Seizure Semiology in Gliobastoma Multiforme As Presenting Sign Seizures 123 ( 42.1 % ) 181 ( 62 % ) Secondary Generalized Simple Partial Combined Partial & Sec. Generalized Complex Partial 74 ( 40.8 % ) 59 ( 32.6 % ) 26 ( 14.4 % ) 9 ( 5 % ) De Wit - Kerkhof, 2012

Standard Treatment in Glioblastoma Multiforme (GBM) Chemoradiation with Temozolomide particularly effective with methylated MGMT Methylation Status of MGMT Stupp, 2005

Effect of Radiation Therapy and of Systemic Chemotherapy EORTC Study on Radiotherapy in LGG Seizure-Freedom with Early RT: 75 % ( n = 314) Late RT: 59 % Temozolomide in Low-grade Gliomas TMZ Cohort n=39; Control group n=30 Median length of F-U: 39 vs. 37 Months > 50 % Decrease in Sz frequency With TMZ : 59 %; Control group: 13 % (p <. 001) Van den Bent 2005; Sherman, 2011

Recommendations Refractory Epilepsy Consider Surgery (rather than Wait & See) Consider Radiotherapy & Chemotherapy Luyken, 2003, Soffietti 2005, Englot 2012